Triple Negative Breast Cancer, Immunotherapy, Tumor microenvironment, Patient selection, Cancer Associated Fibroblasts, Preclinical Models Ghent University
Triple
-negative breast cancer (TNBC) represents 15–20% of all breast cancers (BC) and has the worst outcome of all BC subtypes. Although anti-PD-L1 immune checkpoint blockade (ICB) combined with chemotherapy can improve the outcome only for some patients, clinical benefits remain modest and restricted to a subset of patients. Consequently, there is an important need to define biomarkers that more effectively identify patients who ...